Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema:
NCT ID: NCT05847088
Last Updated: 2023-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
58 participants
OBSERVATIONAL
2023-02-15
2023-04-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant
NCT05978622
Short-term Effect of Intravitreal Dexamethasone Implant in Refractory Diabetic Macular Edema
NCT05736081
Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema
NCT02471651
A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema
NCT00168389
Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study
NCT02804360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intravitreal Dexamethasone Implant for refractory Diabetic macular edema:
Intravitreal Dexamethasone implants (DEX) (0.7 mg) (Ozurdex, Allergan, Inc, Irvine, CA, USA) had been used with greater efficacy and safety in DME.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sex: both
* NTDME with CMT \>300 u
* \< 10% reduction in CMT (than previous treatment)
* \< 50 u reduction in CMT (than previous treatment)
* Worsening of BCVA \> 1 line on E chart.
* Duration since Previous treatment is: 3 months with DEX, 1 month with Anti-VEGF
* Pseudophakic eyes
* NPDR , PRP-treated PDR
Exclusion Criteria
* Uncontrolled Glaucoma (IOP \> 24 mmHg, or cup disc ratio 0.8 or more)
* Herpetic viral infection.
* Untreated PDR
16 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dar El Oyoun Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wael Ahmed Ewais
Associate professor of Ophthalmology Cairo university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kasr alainy faculty of medicine
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N-21-2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.